| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| LYT-200 | LYT-200 | Phase 2 Clinical | Puretech Health | Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours | Details |
| Anti-Gal9 antibody (Fibrogen) | FG-3165; HFB-200901; HFB-200902; HFB2009; HFB2009 series; HFB9-2 | Phase 1 Clinical | HiFiBiO Therapeutics | Solid tumours | Details |